Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1045 in Systemic Lupus Erythematosus and Rheumatoid Arthritis
NCT07363590Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2026
- Primary completion
- Jul 2029
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 1, open-label trial of CN201 in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) (3 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants with One or More Adverse Events at 52 weeks and Number of Participants who Discontinue Study Drug Due to an AE at 4 weeks. Started Feb 2026; status: recruiting.
02
Drugs
CN201
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07363590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07363590.